PeptideDeck
HomePeptidesExenatide
Weight Loss / Diabetes
Half-life: ~2.4 hours (Byetta); ~2 weeks effective (Bydureon extended-release)
Last updated: March 18, 2026

Exenatide

Exenatide (Byetta, Bydureon)

Recommended

Purchase Exenatide

Buy Exenatide — 50% Off
Exenatide is a GLP-1 receptor agonist originally isolated from the saliva of the Gila monster lizard (Heloderma suspectum). It was the first GLP-1 agonist approved by the FDA (2005), pioneering the drug class that now includes semaglutide and tirzepatide. Exenatide shares about 53% sequence homology with human GLP-1 but is resistant to DPP-4 degradation, giving it a longer half-life. It's available as twice-daily injection (Byetta) or once-weekly extended-release formulation (Bydureon). While newer GLP-1 agonists have surpassed it in efficacy and convenience, exenatide established the proof-of-concept for the entire drug class.
Recommended Supplier

Get Exenatide

Sourced from Ascension Peptides. Verified ≥Pharmaceutical grade purity, third-party tested. COA included.

Buy Exenatide — 50% Off
50%

Off with code

PEPTIDEDECK

Table of Contents

What is Exenatide?

Exenatide is the founding member of the GLP-1 receptor agonist drug class, originally isolated from the saliva of the Gila monster lizard. Approved by the FDA in 2005 as Byetta (twice-daily) and later as Bydureon (once-weekly), it established the proof-of-concept that incretin-based therapies could effectively treat type 2 diabetes while promoting weight loss.

The discovery of exenatide traces to researcher John Eng, who in the 1990s identified exendin-4 in Gila monster venom. This peptide activates human GLP-1 receptors but is naturally resistant to DPP-4 degradation—the enzyme that breaks down natural GLP-1 within minutes. This stability made it suitable for drug development.

While semaglutide, tirzepatide, and liraglutide have since surpassed exenatide in efficacy and market share, exenatide remains historically important as the drug that proved GLP-1 agonists could work—paving the way for the entire class that has transformed diabetes and obesity treatment.

Research Benefits

First FDA-approved GLP-1 agonist (2005)

Proven efficacy for blood sugar control

Moderate weight loss effects

Available in twice-daily and once-weekly forms

Extensive long-term safety data

Lower cost than newer GLP-1 agonists

Does not require dose titration (Bydureon)

Natural origin (Gila monster peptide)

How Exenatide Works

Exenatide activates GLP-1 receptors with similar effects to native GLP-1 but with extended duration of action due to resistance to enzymatic degradation.

GLP-1 Receptor Activation

Like other GLP-1 agonists, exenatide:

  • Enhances glucose-dependent insulin secretion
  • Suppresses glucagon release
  • Slows gastric emptying
  • Reduces appetite through CNS effects

Extended-Release Mechanism

Bydureon uses microsphere technology: exenatide is encapsulated in biodegradable polymer spheres that slowly release the peptide over weeks. This provides steady drug levels without the peaks and troughs of immediate-release Byetta.

Research Applications

Type 2 diabetes management

Active research area with published studies

GLP-1 receptor pharmacology

Active research area with published studies

Incretin-based therapy research

Active research area with published studies

Beta cell function preservation

Active research area with published studies

Cardiovascular outcomes (EXSCEL trial)

Active research area with published studies

Weight management in diabetes

Active research area with published studies

Research Findings

Exenatide has extensive clinical trial data as the first approved GLP-1 agonist.

Efficacy Trials

The original development program showed HbA1c reductions of 0.8-1.0% and average weight loss of 2-4 kg—significant at the time of approval but modest by current standards.

EXSCEL Cardiovascular Trial

The EXSCEL trial examined cardiovascular outcomes in 14,752 patients. Results showed exenatide was non-inferior to placebo for cardiovascular safety, but didn't achieve statistical significance for cardiovascular benefit (unlike semaglutide's SUSTAIN-6 or liraglutide's LEADER).

PureBac 7x tested bacteriostatic water 10mL vial
7x Quality Tested Bac Water

Don't ruin a $300 peptide on generic bac water.

Sterile, non-pyrogenic, exactly 0.9% benzyl alcohol, with a COA on every batch. Made for peptide reconstitution, not repackaged from generic stock.

0.9% benzyl alcohol 7x tested in USA COA every batch
Get PureBac bac water From $7.99 · Free shipping over $150

Dosage & Administration

Exenatide is available in two formulations with different dosing schedules.

Byetta (Twice-Daily)

  • Starting dose: 5 mcg twice daily before meals
  • Maintenance: 10 mcg twice daily
  • Must inject within 60 minutes before meals

Bydureon (Once-Weekly)

  • Fixed dose: 2 mg once weekly
  • No dose titration required
  • Can be given any time, with or without food

Work out your Exenatide draw in units

Enter the vial size, the bacteriostatic water you add and the dose you want, and the calculator gives the syringe units, how long the vial lasts and when to discard it.

Open the peptide calculator

Safety & Side Effects

Exenatide's safety profile is well-established from over 15 years of clinical use.

Common Effects

  • Nausea (improves over time)
  • Vomiting, diarrhea
  • Injection site reactions (especially Bydureon nodules)

Warnings

Same boxed warning about thyroid C-cell tumors as other GLP-1 agonists. Reports of pancreatitis have prompted cautionary labeling.

Frequently Asked Questions

How was exenatide discovered in Gila monster venom?
In the 1990s, researcher John Eng identified a peptide called exendin-4 in Gila monster saliva that powerfully activated GLP-1 receptors. The Gila monster uses this peptide to regulate its own metabolism during infrequent meals (they may eat only a few times per year). Exendin-4 shares 53% sequence similarity with human GLP-1 but is naturally resistant to DPP-4, the enzyme that rapidly degrades natural GLP-1. This made it an ideal candidate for drug development, eventually becoming exenatide—the founding member of the GLP-1 agonist drug class.
What's the difference between Byetta and Bydureon?
Both contain exenatide but in different formulations. Byetta is immediate-release exenatide requiring twice-daily injection before meals—inconvenient but allows quick dose adjustments. Bydureon is extended-release exenatide in microspheres that slowly release the drug over a week, requiring only once-weekly injection but with fixed dosing. Bydureon provides smoother drug levels but takes longer to reach steady state (about 10 weeks). Most patients prefer the once-weekly convenience of Bydureon.
How does exenatide compare to newer GLP-1 agonists?
Newer GLP-1 agonists like semaglutide and tirzepatide have surpassed exenatide in efficacy. Head-to-head trials show semaglutide produces greater HbA1c reduction and significantly more weight loss. The main advantages exenatide retains are: (1) longer track record with more safety data, (2) lower cost (especially generic Byetta), (3) historical significance as the first GLP-1 agonist. For maximum efficacy, newer agents are preferred; exenatide remains an option when cost is a factor or newer agents aren't tolerated.
What weight loss occurs with exenatide?
Exenatide produces modest weight loss—typically 2-4 kg (4-9 lbs) in clinical trials over 6-12 months. This is less than the 10-15% body weight loss seen with higher doses of semaglutide. Exenatide is approved for diabetes rather than obesity; weight loss is considered a beneficial side effect rather than the primary goal. For patients whose main objective is weight loss, semaglutide or tirzepatide are more effective options.
What are the side effects of exenatide?
Side effects are similar to other GLP-1 agonists: nausea (most common, especially at treatment start), vomiting, diarrhea, and injection site reactions (particularly with Bydureon which can cause nodules). Hypoglycemia risk increases when combined with insulin or sulfonylureas. Exenatide carries the same boxed warning about thyroid C-cell tumors as other GLP-1 agonists. Post-marketing reports have linked it to pancreatitis, though causation remains debated. Overall tolerability is comparable to other agents in the class.
Is exenatide still used?
Yes, though less commonly than newer GLP-1 agonists. Exenatide remains useful for: patients who respond well to it and don't want to switch, cost-sensitive situations where newer agents are unaffordable, patients who don't tolerate semaglutide or other newer options, and educational/research purposes as the founding GLP-1 agonist. Its market share has declined significantly with the success of semaglutide and tirzepatide, but it remains available and effective.

Scientific References

1

Exenatide: a review of its use in type 2 diabetes mellitus

Drugs (2006)

2

Effects of exenatide (exendin-4) on glycemic control over 30 weeks

Diabetes Care (2005)

3

Effects of exenatide on cardiovascular events (EXSCEL)

New England Journal of Medicine (2017)

4

Discovery and development of exenatide

Current Opinion in Investigational Drugs (2007)

Quick Reference

Molecular Weight4,186.6 Da
Half-Life~2.4 hours (Byetta); ~2 weeks effective (Bydureon extended-release)
PurityPharmaceutical grade
FormSolution (Byetta) or extended-release suspension (Bydureon)
SupplierAscension Peptides

Sequence

His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 (39 amino acids)

Storage

Refrigerate; Byetta can be at room temperature for 30 days once in use

Related Peptides

Dulaglutide
Weight Loss & Metabolic
Liraglutide
Weight Loss & Metabolic
Semaglutide
Metabolic
Tirzepatide
Metabolic